Cubist Tedizolid Advisory Cmte. Review Will Gauge FDA’s Mood On Antibiotic “Breakpoints”
This article was originally published in The Pink Sheet Daily
Executive Summary
Cubist’s second-generation oxazolidineone is set for an FDA advisory committee review in March.